Franklin Street Advisors Inc. NC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Franklin Street Advisors Inc. NC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 63.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 22,688 shares of the company’s stock after selling 39,312 shares during the period. Franklin Street Advisors Inc. NC’s holdings in Johnson & Johnson were worth $3,316,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Beacon Financial Planning Inc. boosted its position in shares of Johnson & Johnson by 8.2% during the 2nd quarter. Beacon Financial Planning Inc. now owns 5,603 shares of the company’s stock worth $819,000 after purchasing an additional 423 shares in the last quarter. Intellectus Partners LLC boosted its position in shares of Johnson & Johnson by 11.2% during the 2nd quarter. Intellectus Partners LLC now owns 8,854 shares of the company’s stock worth $1,294,000 after purchasing an additional 895 shares in the last quarter. Harrell Investment Partners LLC boosted its position in shares of Johnson & Johnson by 6.5% in the 2nd quarter. Harrell Investment Partners LLC now owns 36,526 shares of the company’s stock worth $5,339,000 after buying an additional 2,245 shares in the last quarter. Everpar Advisors LLC boosted its position in shares of Johnson & Johnson by 23.1% in the 2nd quarter. Everpar Advisors LLC now owns 9,155 shares of the company’s stock worth $1,338,000 after buying an additional 1,720 shares in the last quarter. Finally, Peddock Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 1.1% in the 2nd quarter. Peddock Capital Advisors LLC now owns 9,808 shares of the company’s stock worth $1,434,000 after buying an additional 109 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ traded up $0.30 on Friday, reaching $159.39. The stock had a trading volume of 5,012,774 shares, compared to its average volume of 7,341,345. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.39. The firm’s fifty day moving average is $152.38 and its two-hundred day moving average is $153.10. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market cap of $383.60 billion, a price-to-earnings ratio of 9.94, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the company posted $2.80 EPS. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 5th. The Goldman Sachs Group decreased their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Finally, TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.